MedTrace Logo

Anaesthesiologic Considerations for Intraoperative ECMO Anticoagulation During Lung Transplantation

NCT06054997 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 141

Last updated 2023-10-03

No results posted yet for this study

Summary

Extracorporeal membrane oxygenation (ECMO) is a frequently used extracorporeal support measure during the intraoperative period in lung transplantation. A certain amount of anticoagulation, mainly unfractionated heparin (UFH), is used as part of ECMO support. One of the most common perioperative complications during lung transplantation is bleeding. An inadequately high dose of UFH can increase the risk of bleeding. In this study, the investigators hypothesised that a lower dose of UFH would decrease the risk of nonsurgical bleeding complications during lung transplantation and would not pose an increased risk of thrombotic complications for patients or ECMO circuits.

Conditions

  • Lung Transplantation

Sponsors & Collaborators

  • University Hospital, Motol

    lead OTHER

Principal Investigators

  • Jaromir Vajter, Dr., MD · University Hospital in Motol

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-01
Primary Completion
2022-12-31
Completion
2023-08-01

Countries

  • Czechia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06054997 on ClinicalTrials.gov